Wave Life Sciences从GSK手中重新获得WVE-006的全部权利

2026-02-02 20:33

This follows agreement with GSK, whose respiratory portfolio is focused on large-scale diseases, that Wave is well placed to efficiently advance the WVE-006 program in AATD, a rare condition.
This agreement was made prior to data becoming available from the next cohort of the RestorAATion-2 clinical trial, which remains on track for the first quarter of 2026.
Wave is now accelerating its registrational strategy for WVE-006 and plans to engage with the U.S. Food and Drug Administration (FDA) on a potential accelerated approval pathway, with regulatory feedback expected mid-2026.
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address both lung and liver manifestations of this disease
Wave plans to engage FDA on potential accelerated approval pathway for WVE-006, with regulatory feedback anticipated mid-2026
Data from the 400 mg multidose cohort of RestorAATion-2 clinical trial remain on track for first quarter of 2026 and data from the 600 mg single and multidose cohorts are expected in 2026
Research collaboration with GSK is ongoing and continues to expand with fourth program now selected to advance
Wave continues to expect cash runway into 3Q 2028